Lahouaria Hadri

Dr. Lahouaria Hadri

Icahn School of Medicine at Mount Sinai, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2016 in Nature Communications
Verified
Journal Article
Open access
SESolene Evrard
Solene Evrard
LLLaura Lecce
Laura Lecce
KMKatherine C. Michelis
Katherine C. Michelis
ANAya Nomura-Kitabayashi
Aya Nomura-Kitabayashi
GPGaurav Pandey
Gaurav Pandey
JKJason C. Kovacic
Jason C. Kovacic
Endothelial to mesenchymal transition (EndMT) plays a major role during development, and also contributes to several adult cardiovascular diseases. Importantly, mesenchymal cells including fibroblasts are prominent in atherosclerosis, with key functions including regulation of: inflammation, matrix and collagen production, and plaque structural integrity. However, little is known about the origins of atherosclerosis-associated fibroblasts. Here we show using endothelial-specific lineage-tracking that EndMT-derived fibroblast-like cells are common in atherosclerotic lesions, with EndMT-derived cells expressing a range of fibroblast-specific markers. In vitro modelling confirms that EndMT is driven by TGF-β signalling, oxidative stress and hypoxia; all hallmarks of atherosclerosis. ‘Transitioning’ cells are readily detected in human plaques co-expressing endothelial and fibroblast/mesenchymal proteins, indicative of EndMT. The extent of EndMT correlates with an unstable plaque phenotype, which appears driven by altered collagen-MMP production in EndMT-derived cells. We conclude that EndMT contributes to atherosclerotic patho-biology and is associated with complex plaques that may be related to clinical events.

1 March 2008 in JACC
Verified
Journal Article
Closed access
YKYoshiaki Kawase
Yoshiaki Kawase
HLHung Q. Ly
Hung Q. Ly
FPFabrice Prunier
Fabrice Prunier
DLDjamel Lebeche
Djamel Lebeche
YSYanfen Shi
Yanfen Shi
RHRoger J. Hajjar
Roger J. Hajjar

10 March 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
LSLennart Suckau
Lennart Suckau
HFHenry Fechner
Henry Fechner
ECElie Chemaly
Elie Chemaly
SKStefanie Krohn
Stefanie Krohn
Lahouaria HadriLahouaria Hadri
Lahouaria Hadri
Wolfgang PollerWolfgang Poller
Wolfgang Poller
Background— RNA interference (RNAi) has the potential to be a novel therapeutic strategy in diverse areas of medicine. Here, we report on targeted RNAi for the treatment of heart failure, an important disorder in humans that results from multiple causes. Successful treatment of heart failure is demonstrated in a rat model of transaortic banding by RNAi targeting of phospholamban, a key regulator of cardiac Ca 2+ homeostasis. Whereas gene therapy rests on recombinant protein expression as its basic principle, RNAi therapy uses regulatory RNAs to achieve its effect. Methods and Results— We describe structural requirements to obtain high RNAi activity from adenoviral and adeno-associated virus (AAV9) vectors and show that an adenoviral short hairpin RNA vector (AdV-shRNA) silenced phospholamban in cardiomyocytes (primary neonatal rat cardiomyocytes) and improved hemodynamics in heart-failure rats 1 month after aortic root injection. For simplified long-term therapy, we developed a dimeric cardiotropic adeno-associated virus vector (rAAV9-shPLB) to deliver RNAi activity to the heart via intravenous injection. Cardiac phospholamban protein was reduced to 25%, and suppression of sacroplasmic reticulum Ca 2+ ATPase in the HF groups was rescued. In contrast to traditional vectors, rAAV9 showed high affinity for myocardium but low affinity for liver and other organs. rAAV9-shPLB therapy restored diastolic (left ventricular end-diastolic pressure, dp/dt min , and τ) and systolic (fractional shortening) functional parameters to normal ranges. The massive cardiac dilation was normalized, and cardiac hypertrophy, cardiomyocyte diameter, and cardiac fibrosis were reduced significantly. Importantly, no evidence was found of microRNA deregulation or hepatotoxicity during these RNAi therapies. Conclusions— Our data show for the first time the high efficacy of an RNAi therapeutic strategy in a cardiac disease.

27 October 2009 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
LLLarissa Lipskaia
Larissa Lipskaia
ECElie R Chemaly
Elie R Chemaly
Lahouaria HadriLahouaria Hadri
Lahouaria Hadri
ALAnne-Marie Lompre
Anne-Marie Lompre
RHRoger J Hajjar
Roger J Hajjar
(2010). Sarcoplasmic reticulum Ca2+ ATPase as a therapeutic target for heart failure. Expert Opinion on Biological Therapy: Vol. 10, No. 1, pp. 29-41.

16 August 2011 in Circulation
Verified
Journal Article
Closed access
PDF file
JHJean-Sébastien Hulot
Jean-Sébastien Hulot
JFJérémy Fauconnier
Jérémy Fauconnier
DRDeepak Ramanujam
Deepak Ramanujam
ACAntoine Chaanine
Antoine Chaanine
FAFleur Aubart
Fleur Aubart
SEStefan Engelhardt
Stefan Engelhardt
Background—: Cardiomyocytes use Ca 2+ not only in excitation-contraction coupling but also as a signaling molecule promoting, for example, cardiac hypertrophy. It is largely unclear how Ca 2+ triggers signaling in cardiomyocytes in the presence of the rapid and large Ca 2+ fluctuations that occur during excitation-contraction coupling. A potential route is store-operated Ca 2+ entry, a drug-inducible mechanism for Ca 2+ signaling that requires stromal interaction molecule 1 (STIM1). Store-operated Ca 2+ entry can also be induced in cardiomyocytes, which prompted us to study STIM1-dependent Ca 2+ entry with respect to cardiac hypertrophy in vitro and in vivo. Methods and Results—: Consistent with earlier reports, we found drug-inducible store-operated Ca 2+ entry in neonatal rat cardiomyocytes, which was dependent on STIM1. Although this STIM1-dependent, drug-inducible store-operated Ca 2+ entry was only marginal in adult cardiomyocytes isolated from control hearts, it increased significantly in cardiomyocytes isolated from adult rats that had developed compensated cardiac hypertrophy after abdominal aortic banding. Moreover, we detected an inwardly rectifying current in hypertrophic cardiomyocytes that occurs under native conditions (ie, in the absence of drug-induced store depletion) and is dependent on STIM1. By manipulating its expression, we found STIM1 to be both sufficient and necessary for cardiomyocyte hypertrophy in vitro and in the adult heart in vivo. Stim1 silencing by adeno-associated viruses of serotype 9–mediated gene transfer protected rats from pressure overload–induced cardiac hypertrophy. Conclusion—: By controlling a previously unrecognized sarcolemmal current, STIM1 promotes cardiac hypertrophy.

30 July 2013 in Circulation
Verified
Journal Article
Closed access
PDF file
Lahouaria HadriLahouaria Hadri
Lahouaria Hadri
RKRazmig G. Kratlian
Razmig G. Kratlian
LBLudovic Benard
Ludovic Benard
BMBradley A. Maron
Bradley A. Maron
PDPeter Dorfmüller
Peter Dorfmüller
JLJane A. Leopold
Jane A. Leopold
Background—: Pulmonary arterial hypertension (PAH) is characterized by dysregulated proliferation of pulmonary artery smooth muscle cells leading to (mal)adaptive vascular remodeling. In the systemic circulation, vascular injury is associated with downregulation of sarcoplasmic reticulum Ca 2+ -ATPase 2a (SERCA2a) and alterations in Ca 2+ homeostasis in vascular smooth muscle cells that stimulate proliferation. We, therefore, hypothesized that downregulation of SERCA2a is permissive for pulmonary vascular remodeling and the development of PAH. Methods and Results—: SERCA2a expression was decreased significantly in remodeled pulmonary arteries from patients with PAH and the rat monocrotaline model of PAH in comparison with controls. In human pulmonary artery smooth muscle cells in vitro, SERCA2a overexpression by gene transfer decreased proliferation and migration significantly by inhibiting NFAT/STAT3. Overexpresion of SERCA2a in human pulmonary artery endothelial cells in vitro increased endothelial nitric oxide synthase expression and activation. In monocrotaline rats with established PAH, gene transfer of SERCA2a via intratracheal delivery of aerosolized adeno-associated virus serotype 1 (AAV1) carrying the human SERCA2a gene (AAV1.SERCA2a) decreased pulmonary artery pressure, vascular remodeling, right ventricular hypertrophy, and fibrosis in comparison with monocrotaline-PAH rats treated with a control AAV1 carrying β-galactosidase or saline. In a prevention protocol, aerosolized AAV1.SERCA2a delivered at the time of monocrotaline administration limited adverse hemodynamic profiles and indices of pulmonary and cardiac remodeling in comparison with rats administered AAV1 carrying β-galactosidase or saline. Conclusions—: Downregulation of SERCA2a plays a critical role in modulating the vascular and right ventricular pathophenotype associated with PAH. Selective pulmonary SERCA2a gene transfer may offer benefit as a therapeutic intervention in PAH.